今天3分钟我们来聊聊8月6日FDA正式批准溶瘤病毒疗法治疗晚期黑色素瘤

2026年8月，FDA批准第二款溶瘤病毒疗法Tudriqev，用于PD-1耐药的晚期黑色素瘤。改造疱疹病毒注射入肿瘤后溶瘤释放抗原，激活免疫系统并联合O药，24.2%患者肿瘤缩小，中位缓解持续14.1个月，为无药可用患者带来新希望。参考文献：FDA. FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma. 2026-08-06. https://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanomaFDA. FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma. 2026-08-06. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanomaReplimune. IGNYTE Trial Presentation, FDA CTGTAC Meeting. 2026-07-30. https://ir.replimune.com/static-files/a82408df-4a03-4589-8742-a9bb672e20ddReplimune. 3-Year Landmark OS Analysis from IGNYTE, ASCO 2026. https://ir.replimune.com/news-releases/news-release-details/replimune-presents-3-year-landmark-overall-survival-analysisIGNYTE Trial (NCT03767348), RP1 + Nivolumab in Advanced Anti-PD-1-Failed Melanoma. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12622257/前往小宇宙评论区与主播互动